<DOC>
	<DOCNO>NCT02689258</DOCNO>
	<brief_summary>A Phase 2 , Randomized , Controlled Evaluation Efficacy Safety HTX-011 HTX-002 Post-Operative Analgesia Following Abdominoplasty Surgery</brief_summary>
	<brief_title>Evaluation Efficacy Safety HTX-011 Postoperative Analgesia Following Abdominoplasty Surgery</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Subjects must meet follow criterion consider eligible participate study : 1 . Be schedule undergo abdominoplasty surgery amenable treatment long act local anesthetic per anesthesia protocol 2 . Be American Society Anesthesiology ( ASA ) physical Class I II 3 . Subjects 18 year age old 4 . Have clinical laboratory value within normal limit ( WNL ) ; subject AST/ALT &lt; 3 x ULN , and/or creatinine &lt; 2 x ULN acceptable . 5 . Have body mass index â‰¤ 30 kg/m2 6 . Female subject eligible follow apply : Not pregnant ( female subject child bear potential must negative serum pregnancy test screen negative urine pregnancy test surgery ) Not lactate Not plan become pregnant study Be surgically sterile ; least two year postmenopausal ; monogamous partner surgically sterile ; practice doublebarrier contraception ; practice abstinence ( must agree use doublebarrier contraception event sexual activity ) ; use insertable , injectable , transdermal , combination oral contraceptive approve FDA great 2 month prior screen visit commits use acceptable form birth control duration study 7 . Male subject must surgically sterile ( biologically surgically ) commit use reliable method birth control duration study 8 . Does NOT , determine investigator study 's medical monitor , history clinical manifestation significant renal , hepatic , cardiovascular , metabolic , neurologic , psychiatric , condition would preclude participation study 9 . Must able understand study procedure willing comply give informed consent conduct study procedure , use IRB approve consent Subjects meet follow criterion exclude participate study : 1 . Have contraindication allergic medication use trial period 2 . Have another painful physical condition , opinion investigator , may confound assessment postoperative pain 3 . Have history migraine frequent headache , seizure , currently take anticonvulsant 4 . Currently take analgesic chronically painful condition , take long acting opioids within 3 day surgery , take opioids within 24 hour surgery 5 . Previous abdominal surgery , determine investigator , would preclude participation study 6 . Subjects require liposuction part abdominoplasty procedure Part A protocol 7 . Subjects ancillary procedure perform abdominoplasty surgery unrelated abdominal area ( breast reduction , breast augmentation , etc . ) 8 . Subjects unable discontinue medication stable dose least 14 day prior schedule abdominoplasty procedure dose investigational product 9 . Subjects take following medication ; anticonvulsant , sedative ( include benzodiazepine ) corticosteroid ( mean administration ) , nonsteroidal antiinflammatory drug ( NSAIDS ) within 24 hour study drug dosing , morphine , monoamine oxidase inhibitor ( MAOIs ) , tricyclic antidepressant ( TCAs ) , neuroleptic , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) . Gabapentin pregabalin permit 10 . Have know suspected history alcohol drug abuse 11 . Have positive result alcohol breath test indicative alcohol abuse urine drug screen indicative illicit drug use ( unless result explain current prescription acceptable overthecounter medication screening determine investigator ) . The urine drug screen prior surgery must negative 12 . Have evidence clinically significant 12lead ECG abnormality accord judgment investigator 13 . Have receive investigational product within 30 day start study 14 . Have previously receive HTX011 clinical trial 15 . Experiences clinically significant event surgery prior administration investigational product ( e.g. , excessive bleeding , hemodynamic instability ) would render subject medically unstable , complicate postsurgical course , significantly increase risk study drug administration per judgment investigator . This result subject report randomized , treat . 16 . Subjects sleep apnea home continuous positive airway pressure ( CPAP ) 17 . Subjects receive oxygen therapy time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>